Home › Companies › NRIX

Nurix Therapeutics, Inc.

NRIX Lead: Phase 2 1 Biotech Distilled article ↓

Oncology Small Molecule

Most recent annual filing: 2026-01-28

Pipeline (13 active programs)

bexobrutideg

NX-5948

Small Molecule Target: BTK

Chronic Lymphocytic Leukemia Phase 2 oral
Small Lymphocytic Lymphoma Phase 2 oral
Waldenström's Macroglobulinemia Phase 1 oral
Follicular Lymphoma Phase 1 oral
Marginal Zone Lymphoma Phase 1 oral

zelebrudomide

NX-2127

Small Molecule Target: BTK, IKZF1, IKZF3

Diffuse Large B-Cell Lymphoma Phase 1 oral
Mantle Cell Lymphoma Phase 1 oral
Chronic Lymphocytic Leukemia Phase 1 oral
Marginal Zone Lymphoma Phase 1 oral
Waldenström's Macroglobulinemia Phase 1 oral

NX-1607

Small Molecule Target: CBL-B

Undisclosed indication Phase 1 oral

NX-0479

GS-6791

Small Molecule Target: IRAK4

Undisclosed indication Phase 1 Gilead Sciences

NX-3911

Small Molecule Target: STAT6

Undisclosed indication Preclinical Sanofi

Technology platforms

DEL-AI

Fully AI-integrated, DNA-encoded library (DEL)-powered drug discovery engine for targeted protein degradation (TPDs and DACs); disease-agnostic; applied to oncology, inflammation, autoimmunity and other therapeutic areas; leverages 5 billion DEL compounds and machine learning for ligand discovery, degrader design, and optimization.

DAC · Pfizer

Degrader Antibody Conjugate platform combining targeted protein degrader payloads with cell/tissue-selective antibody delivery; designed for oncology and non-oncology; partnered with Pfizer for ADC/DAC development.

Biotech Distilled coverage (1)

2026-04-13 Nurix Therapeutics (NRIX) - Scientific Deep Dive for Bexobrutideg and Pipeline Products 🔒 Paid

Articles open on Substack. Some deep dives are subscriber-only.